On June 17, the U.S. FDA issued a Class I recall notice — Dexcom, a major player in diabetes management, is recalling products due to an alarm functionality defect.Global Recall of More Than 2 Million CGMs(Continuous Glucose Monitoring) Receiver Device.

This recall involves almost all mainstream product lines under Decans Medical:G7, G6, One, and One+ SystemsThe receiver component.As of May, the company had received 56 reports of serious adverse events, including critical conditions triggered by hypoglycemia or hyperglycemia such as seizures and loss of consciousness.

This is one of the largest recall events in Decans' history. GloballyThe leading company in the CGM field, Decans Medical, has achieved a market value of nearly 50 billion US dollars with a single product.

Alarm Silence: Level 1 Recall Storm

According toAccording to the recall database information released by the FDA, the core issue of this recall is a manufacturing defect in the receiver component — problematic foam or assembly errors may cause the receiver speaker to lose contact with the printed circuit board, resulting in the device's inability to emit audible alarms.

"When patients are asleep or unable to check their devices, audible alerts are a critical warning method," Decans warned in a letter to customers. "Missing an alert could lead to untreated hypoglycemia or hyperglycemia, potentially resulting in seizures, vomiting, loss of consciousness, or even death."

Although the affected devices can still provide alerts through vibration and visual cues, the absence of audible alarms may lead to serious consequences in specific scenarios.

According to the data disclosed by Decans, this recall involvesMore than 1.9 million G7 receivers、182,000 G6 Receivers, and76,000 units of the One systemAnd59,000 units of the One+ systemEquipment. The proportion of affected users is approximately 0.015%.

Decans Medical has requested users to contact the technical support department to coordinate returns and receive free replacements, while also recommending all users to regularly test the device speaker functionality.

Technical Core: DecansDecoding CGM Products

Decans' CGM system represents the advanced blood glucose monitoring technology of today. Its flagship product, the G6 system, consists of three core components:Sensor、TransmitterAndDisplay Device(Dedicated receiver or smartphone application).

The revolutionary calibration-free design isThe biggest breakthrough of G6. Unlike previous generations, G6 is factory-calibrated, and users only need to input the unique calibration code for each sensor to achieve "zero fingerstick" monitoring (unless alarms do not match symptoms).

SystemEveryAutomatic Acquisition in 5 MinutesA glucose reading from the interstitial fluid of subcutaneous tissue is transmitted to a display device via Bluetooth. Users can view their blood glucose values, trend arrows, and blood glucose curves from the past several hours anytime, anywhere.

DecansThe innovative application experience of G6 is equally impressive:

• Real-time Alert System：Customizable high and low blood glucose threshold alerts, newly added"Emergency Alert" can warn 20 minutes before severe hypoglycemia (55mg/dL) occurs;

• Data Sharing Function：ThroughDexcom Share allows patients to share their blood glucose data in real-time with family members or healthcare providers.

• Multi-platform Support：Data can be synchronized toSmart watches like Apple Watch allow for convenient viewing anytime, anywhere.

Sensor service life is10 days, the transmitter can last for three months. Many users extend the use of a single sensor to 20-30 days through "sensor restart" to reduce costs.

From Startups to Industry Giants

The growth trajectory of Decans Medical is nothing short of a legend in the field of medical technology. The company was founded inFrom 1999, growing from a small enterprise with only US$100 million in revenue in 2012 to an industry giant with US$3.622 billion in revenue by 2023, achieving a compound annual growth rate of 38.6% over 11 years.

Behind this astonishing growth, Decans Medical has accurately seized the globalOpportunities for CGM Market Expansion:

• 2017 Milestones:United StatesCMS inclusion of CGM into the Medicare coverage range has significantly improved product accessibility;

• Policy Breakthroughs in 2023:Medicare further expands its coverage to include patients using only basal insulin and non-insulin-dependent Type II diabetes patients with hypoglycemic events.

• Acceleration of Market Globalization:In the third quarter of 2023, Decans' market in the United States grew by 24%, while the international market growth rate reached 33%.

As ofIn May 2024, Decans Medical's market value approached $50 billion, becoming a model for top-tier enterprises in the global medical device field with a single product line.

CGM Competition Intensifies

As the prevalence of diabetes continues to rise globallyThe CGM market has become one of the most fiercely competitive battlegrounds in the medical device field.

Currently GlobalThe CGM market is mainly dominated byAbbott、DecansAndMedtronicDivided among three leading companies.

According to the company's financial report data, in 2020, the global market shares of Abbott, Decans, and Medtronic were respectively46%、34%、19%Decans Medical primarily focuses on the U.S. market, holding a 56% share in the U.S., while Abbott follows an international strategy, capturing over half of the market outside the U.S.

Two giants adopted differentiated market strategies: Decans inDecans Medical takes the lead in the Type I diabetes field, while Abbott holds a larger market share among Type II diabetes patients. Abbott's FreeStyle series has also seen rapid growth, with revenue soaring from $1.1 billion in 2018 to $5.3 billion in 2023, representing a compound annual growth rate (CAGR) of 37.34%.

New forces are joining the competition:

• Accelerated Technological Iteration：DecansG7, Abbott FreeStyle Libre 3, and other new-generation products continue to improve accuracy and user experience.

• Application Scenario Expansion：GLP-1 Weight Loss Drug Users May Become New Customer Source for CGM

• The Rise of Chinese Enterprises：Sinocare and other Chinese manufacturers are seekingFDA Certification, Planning to Enter the European and American Markets

The market growth potential remains enormous. Decans MedicalThe number of global users by the end of 2024 is approximately2.8M - 2.9M, and the number of people with diabetes worldwide has exceeded500 million, CGM penetration still has significant room for growth.

From the Chinese market perspective, due to the monopoly by foreign enterprises, high prices are also a current stage issue.A Major Industry Pain Point of CGM Dynamic Blood Glucose Monitors.

Against this backdrop, Chinese manufacturers such as Silicon-based, Meiqi, and Wetai have also started to develop CGM. In 2019, Echometer received NMPA approval for marketing; on November 4, 2021, products from Silicon-based and Wetai were successively approved. Additionally, Yuyue Medical, a leading enterprise in China's blood glucose monitoring field, spent over 400 million yuan to acquire CareT, entering the CGM track.

Industry Trends After the Recall

This large-scale recall is for Decans Medical and even the entireThe CGM Industry Sounds the Alarm for Quality Control. In the FDA's recall classification, Class I is the most serious level, indicating that the use of these devices may cause serious injury or death.

This is not Decans' only quality control issue recently. Earlier this year, the company had already faced problems due toG6 Receivers May Fail to Provide High/Low Blood Sugar Alerts, Prompting a Class II Recall.

System ReliabilityCGM Products Are Crucial. When patients entrust these devices with the authority to make treatment decisions, any technical malfunction can directly endanger lives. The recent issue of audible alarms failing is particularly dangerous because it occurs at the times when patients need the alerts most—during sleep or when they are unable to actively monitor their blood glucose levels.

In the face of challenges, Decans Medical is taking active measures:

• Emergency Replacement Plan:Free replacement service for all affected users;

• Preventive Maintenance Recommendations:It is recommended that users regularly test the device speaker function;

• Application Promotion:Encourage users to use mobile applications as an alternative to dedicated receivers, which are less affected.

As the global burden of diabetes continues to increase,CGM Technology Remains the Future Direction of Diabetes Management. Decans' Recall Crisis Not Only Exposed the Heavy Responsibility of Medical Device Companies but Also Highlighted the Irreplaceable Value of This Technology in Improving Patients' Lives.

In an increasingly competitive market environment, product safety and reliability will determine the success or failure of enterprises more than ever before.